The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Claudin 18.2 Targeted Therapy Market Progress Between 2026 And 2030?
The claudin 18.2 targeted therapy market has shown substantial growth in recent years. It is projected to expand from $1.6 billion in 2025 to $1.98 billion in 2026, registering a compound annual growth rate (CAGR) of 23.7%. This historic growth can be attributed to the rising prevalence of gastric and gastrointestinal cancers, breakthroughs in antibody engineering technologies, an increase in oncology-focused clinical trials, greater investments in targeted cancer therapies, and a deeper understanding of claudin protein biology.
The claudin 18.2 targeted therapy market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a valuation of $4.61 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.5%. Several factors contribute to this projected growth, including a rise in regulatory approvals for targeted oncology medications, a heightened need for individualized cancer care, the broader adoption of combination therapy strategies, increasing investments in the oncology pipeline, and the greater utilization of precision diagnostics. Key trends anticipated during this period encompass an intensified focus on biomarker-guided oncology therapies, accelerated development of claudin 18.2 monoclonal antibodies, the expanding availability of indication-specific targeted treatments, improved integration of companion diagnostics, and a surge in strategic partnerships within precision oncology.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp
What Factors Are Contributing To The Growth Of The Claudin 18.2 Targeted Therapy Market?
The increasing occurrence of gastrointestinal cancers is anticipated to fuel the expansion of the claudin 18.2 targeted therapy market in the future. Gastrointestinal (GI) cancers are defined as malignant growths that develop in any part of the digestive tract, from the esophagus to the rectum. The growth in gastrointestinal cancers is primarily attributed to unhealthy diets, particularly those high in processed foods and low in fiber, which contribute to gut inflammation and heighten cancer risk. Claudin 18.2 targeted therapy addresses gastrointestinal cancers by specifically targeting the Claudin 18.2 protein, which is overexpressed on cancer cells, enabling drugs or antibodies to destroy cancer cells while leaving healthy tissue unharmed and thereby enhancing treatment effectiveness. For example, in June 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths from colorectal cancer were recorded in 2023. Therefore, the rising incidence of gastrointestinal cancers is a significant driver of the claudin 18.2 targeted therapy market’s growth.
How Is The Claudin 18.2 Targeted Therapy Market Categorized Across Its Segment Groups?
The claudin 18.2 targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
What Trends Are Influencing The Claudin 18.2 Targeted Therapy Market?
Major companies operating in the claudin 18.2 targeted therapy market are focusing on developing innovative solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and enhance treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to bind precisely to a single target, such as a protein on the surface of cancer cells, aiding the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, obtained approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, activating the immune system to destroy cancer cells. Clinical trials showed it significantly improves progression-free and overall survival when combined with chemotherapy compared to chemotherapy alone. This innovative therapy provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, fulfilling an unmet need in aggressive gastric cancer.
Which Firms Are Influencing Competition In The Claudin 18.2 Targeted Therapy Market?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Get The Full Claudin 18.2 Targeted Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report
Where Is The Claudin 18.2 Targeted Therapy Market Primarily Concentrated By Region?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Claudin 18.2 Targeted Therapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report
Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Coronavirus Current Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
Next Generation Antibody Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model